MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025)
MapLight Therapeutics recorded quarterly Free Cash Flow of -$47.2 million in Q4 2025, down 118.6% quarter-over-quarter from -$21.6 million in Q4 2024, and down 118.6% year-over-year from $253.8 million in Q4 2024.
MapLight Therapeutics' Free Cash Flow history runs 2 years deep, the most recent figure standing at -$47.2 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 118.6% year-over-year to -$47.2 million; the TTM figure through Dec 2025 stood at -$68.8 million (changed N/A YoY), while the FY2025 annual figure was -$138.6 million, down 74.17% from the prior year.
- Free Cash Flow came in at -$47.2 million for Q4 2025 at MapLight Therapeutics, down from -$21.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.6 million in Q4 2024 to a low of -$47.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -47.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2025 | -47.21 Mn |
| Dec 31, 2024 | -21.59 Mn |
| Dec 31, 2024 | -21.59 Mn |